PI3K/Akt signaling in osteosarcoma

Clinica Chimica Acta

Volumn 444, Issue , 2015, Pages 182-192

  Zhang, Jian ^a   Yu, Xiao Hua ^a   Yan, Yi Guo ^a   Wang, Cheng ^a   Wang, Wen Jun ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Akt; MTOR; OS; PI3K; PTEN

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALPELISIB; APITOLISIB; AZACITIDINE; BUPARLISIB; CAFFEINE; CISPLATIN; DACTOLISIB; DOXORUBICIN; EVEROLIMUS; GENISTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; NATURAL PRODUCT; OXYMATRINE; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PICTILISIB; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; TEPOXALIN; UNINDEXED DRUG; WORTMANNIN;

ABDOMINAL PAIN; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; DIARRHEA; DRUG EFFICACY; ENZYME ACTIVATION; FATIGUE; HUMAN; METASTASIS; MOUTH ULCER; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RASH; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; VOMITING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PATHOLOGY;

HUMANS; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84923327275     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.12.041     Document Type: Review

References (141)

1. Guijarro M.V., Ghivizzani S.C., Gibbs C.P. Animal models in osteosarcoma. Front Oncol 2014, 4:189.
2. Luetke A., Meyers P.A., Lewis I., et al. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 2014, 40:523-532.
3. Porta C., Paglino C., Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 2014, 4:64.
4. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
5. Zhou W., Hao M., Du X., et al. Advances in targeted therapy for osteosarcoma. Discov Med 2014, 17:301-307.
6. Ahmad A., Biersack B., Li Y., et al. Targeted regulation of PI3K/Akt/mTOR/NF-kappaB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anticancer Agents Med Chem 2013, 13:1002-1013.
7. Dobbin Z.C., Landen C.N. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci 2013, 14:8213-8227.
8. Rubashkin M.G., Cassereau L., Bainer R., et al. Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate. Cancer Res 2014, 74:4597-4611.
9. Majchrzak A., Witkowska M., Smolewski P. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large b-cell lymphoma: current knowledge and clinical significance. Molecules 2014, 19:14304-14315.
10. Sarbassov D.D., Guertin D.A., Ali S.M., et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
11. Heras-Sandoval D., Perez-Rojas J.M., Hernandez-Damian J., et al. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal 2014, 26:2694-2701.
12. Inoki K., Li Y., Zhu T., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4:648-657.
13. Chang W., Wei K., Ho L., et al. A critical role for the mTORC2 pathway in lung fibrosis. PLoS One 2014, 9:e106155.
14. Zhu Q., Yang J., Han S., et al. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate 2011, 71:835-845.
15. Boreddy S.R., Pramanik K.C., Srivastava S.K. Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clin Cancer Res 2011, 17:1784-1795.
16. Atif F., Yousuf S., Stein D.G. Anti-tumor effects of progesterone in human glioblastoma multiforme: role of PI3K/Akt/mTOR signaling. J Steroid Biochem Mol Biol 2015, 146:62-73.
17. Ji H., Ding Z., Hawke D., et al. AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis. EMBO Rep 2014, 15:1000.
18. Matsuda S., Kobayashi M., Kitagishi Y. Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol 2013, 2013:472432.
19. Okumura N., Yoshida H., Kitagishi Y., et al. PI3K/AKT/PTEN signaling as a molecular target in leukemia angiogenesis. Adv Hematol 2012, 2012:843085.
20. Kuijjer M.L., van den Akker B.E., Hilhorst R., et al. Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. BMC Med Genomics 2014, 7:4.
21. He J.P., Hao Y., Wang X.L., et al. Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev 2014, 15:5967-5976.
22. Pompetti F., Rizzo P., Simon R.M., et al. Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 1996, 63:37-50.
23. Zhai M., Cong L., Han Y., et al. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion. Tumour Biol 2014, 35:1123-1128.
24. Tang N., Song W.X., Luo J., et al. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008, 466:2114-2130.
25. Zhang Y., Hu H., Song L., et al. Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation. Toxicol Lett 2013, 222:1-9.
26. Zhou R., Zhang Z., Zhao L., et al. Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells. J Orthop Res 2011, 29:846-852.
27. Mirabello L., Yu K., Berndt S.I., et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer 2011, 11:209.
28. Ognjanovic S., Olivier M., Bergemann T.L., et al. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 2012, 118:1387-1396.
29. Sadikovic B., Park P.C., Selvarajah S., et al. Array comparative genomic hybridization in osteosarcoma. Methods Mol Biol 2013, 973:227-247.
30. Sakurai N., Iwamoto S., Miura Y., et al. Novel p53 splicing site mutation in Li-Fraumeni-like syndrome with osteosarcoma. Pediatr Int 2013, 55:107-111.
31. Yao C., Wei J.J., Wang Z.Y., et al. Perifosine induces cell apoptosis in human osteosarcoma cells: new implication for osteosarcoma therapy?. Cell Biochem Biophys 2013, 65:217-227.
32. Levine R.A., Forest T., Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol 2002, 39:372-378.
33. Schaal C., Pillai S., Chellappan S.P. The Rb-E2F transcriptional regulatory pathway in tumor angiogenesis and metastasis. Adv Cancer Res 2014, 121:147-182.
34. Bagatell R., Beliakoff J., David C.L., et al. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer 2005, 113:179-188.
35. Frinc I., Muresan M.S., Zaharie F., et al. Cancer stem-like cells: the dark knights of clinical hematology and oncology. J BUON 2014, 19:328-335.
36. Atlasi Y., Looijenga L., Fodde R. Cancer stem cells, pluripotency, and cellular heterogeneity: a WNTer perspective. Curr Top Dev Biol 2014, 107:373-404.
37. Gong C., Liao H., Wang J., et al. LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human osteosarcoma via down-regulation of PI3K activity. Asian Pac J Cancer Prev 2012, 13:3103-3107.
38. Zhang A., He S., Sun X., et al. Wnt5a promotes migration of human osteosarcoma cells by triggering a phosphatidylinositol-3 kinase/Akt signals. Cancer Cell Int 2014, 14:15.
39. Takagi S., Takemoto A., Takami M., et al. Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis. Cancer Sci 2014, 105:983-988.
40. Nugent M. MicroRNA function and dysregulation in bone tumors: the evidence to date. Cancer Manag Res 2014, 6:15-25.
41. Li G., Cai M., Fu D., et al. Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma. Cell Physiol Biochem 2012, 30:1481-1490.
42. Nakanishi A., Wada Y., Kitagishi Y., et al. Link between PI3K/AKT/PTEN Pathway and NOX proteinin diseases. Aging Dis 2014, 5:203-211.
43. Zhao G., Cai C., Yang T., et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 2013, 8:e53906.
44. Gao Y., Luo L.H., Li S., et al. miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression. Biochem Biophys Res Commun 2014, 444:230-234.
45. Shen L., Chen X.D., Zhang Y.H. MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN. Tumour Biol 2014, 35:2069-2074.
46. Zhang Y., Yang C.Q., Gao Y., et al. Knockdown of CXCR7 inhibits proliferation and invasion of osteosarcoma cells through inhibition of the PI3K/Akt and beta-arrestin pathways. Oncol Rep 2014, 32:965-972.
47. Liu B., Wu Y., Zhou Y., et al. Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells. PLoS One 2014, 9:e93576.
48. Wang T.F., Wang H., Peng A.F., et al. Inhibition of fatty acid synthase suppresses U-2 OS cell invasion and migration via downregulating the activity of HER2/PI3K/AKT signaling pathway in vitro. Biochem Biophys Res Commun 2013, 440:229-234.
49. Liu Z.L., Mao J.H., Peng A.F., et al. Inhibition of fatty acid synthase suppresses osteosarcoma cell invasion and migration via downregulation of the PI3K/Akt signaling pathway in vitro. Mol Med Rep 2013, 7:608-612.
50. Liao C.L., Lai K.C., Huang A.C., et al. Gallic acid inhibits migration and invasion in human osteosarcoma U-2 OS cells through suppressing the matrix metalloproteinase-2/-9, protein kinase B (PKB) and PKC signaling pathways. Food Chem Toxicol 2012, 50:1734-1740.
51. Liu T., Zhou W., Zhang F., et al. Knockdown of IRX2 inhibits osteosarcoma cell proliferation and invasion by the AKT/MMP9 signaling pathway. Mol Med Rep 2014, 10:169-174.
52. Liang W., Gao B., Xu G., et al. Possible contribution of aminopeptidase N (APN/CD13) to migration and invasion of human osteosarcoma cell lines. Int J Oncol 2014, 45:2475-2485.
53. Shang H.S., Chang J.B., Lin J.H., et al. Deguelin inhibits the migration and invasion of U-2 OS human osteosarcoma cells via the inhibition of matrix metalloproteinase-2/-9 in vitro. Molecules 2014, 19:16588-16608.
54. Ramakrishna A., Shreedhar B., Narayan T., et al. Cyclin D1 an early biomarker in oral carcinogenesis. J Oral Maxillofac Pathol 2013, 17:351-357.
55. D'Arcy P., Maruwge W., Wolahan B., et al. Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells. PLoS One 2014, 9:e95136.
56. Zhou X., Yuan B., Yuan W., et al. The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma. Tumour Biol 2014, 35:6539-6547.
57. Rokkaku T., Kimura R., Ishikawa C., et al. Anticancer effects of marine carotenoids, fucoxanthin and its deacetylated product, fucoxanthinol, on osteosarcoma. Int J Oncol 2013, 43:1176-1186.
58. Zhang K., Tian F., Zhang Y., et al. MACC1 is involved in the regulation of proliferation, colony formation, invasion ability, cell cycle distribution, apoptosis and tumorigenicity by altering Akt signaling pathway in human osteosarcoma. Tumour Biol 2014, 35:2537-2548.
59. Cicenas J., Kalyan K., Sorokinas A., et al. Highlights of the latest advances in research on CDK inhibitors. Cancers (Basel) 2014, 6:2224-2242.
60. Liu M., Yang L., Zhang L., et al. Human T-cell leukemia virus type 1 infection leads to arrest in the G1 phase of the cell cycle. J Virol 2008, 82:8442-8455.
61. Sabile A.A., Arlt M.J., Muff R., et al. Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. J Bone Miner Res 2012, 27:58-67.
62. Xu G.P., Zhao W., Zhuang J.P., et al. Matrine inhibits the growth and induces apoptosis of osteosarcoma cells in vitro by inactivating the Akt pathway. Tumour Biol 2014, [Epub ahead of print].
63. Ding L., He S., Sun X. HSP70 desensitizes osteosarcoma cells to baicalein and protects cells from undergoing apoptosis. Apoptosis 2014, 19:1269-1280.
64. Zhang G., Li M., Zhu X., et al. Knockdown of Akt sensitizes osteosarcoma cells to apoptosis induced by cisplatin treatment. Int J Mol Sci 2011, 12:2994-3005.
65. Long X.H., Zhang G.M., Peng A.F., et al. Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro. Oncol Rep 2014, 31:328-334.
66. Xu X., Wang B., Xu Y. Expression of lysyl oxidase in human osteosarcoma and its clinical significance: a tumor suppressive role of LOX in human osteosarcoma cells. Int J Oncol 2013, 43:1578-1586.
67. Tedesco I., Russo M., Bilotto S., et al. Dealcoholated red wine induces autophagic and apoptotic cell death in an osteosarcoma cell line. Food Chem Toxicol 2013, 60:377-384.
68. Li B., Yang Y., Jiang S., et al. Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway. Int J Oncol 2012, 41:1809-1819.
69. Chiu H.W., Lin W., Ho S.Y., et al. Synergistic effects of arsenic trioxide and radiation in osteosarcoma cells through the induction of both autophagy and apoptosis. Radiat Res 2011, 175:547-560.
70. Jin S., Pang R.P., Shen J.N., Huang G., Wang J., Zhou J.G. Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis 2007, 12:1317-1326.
71. Anilkumar U., Prehn J.H. Anti-apoptotic BCL-2 family proteins in acute neural injury. Front Cell Neurosci 2014, 8:281.
72. Lu X., Zhao J., Li T., et al. 5,7-dihydroxy-4'-methoxyisoflavone induces apoptosis by inhibiting the ERK and Akt pathways in human osteosarcoma cells. Connect Tissue Res 2014, 1-14.
73. Liu B., Shi Z.L., Feng J., et al. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int 2008, 32:494-501.
74. Di Fiore R., Guercio A., Puleio R., et al. Modeling human osteosarcoma in mice through 3AB-OS cancer stem cell xenografts. J Cell Biochem 2012, 113:3380-3392.
75. Chandolu V., Dass C.R. Cell and molecular biology underpinning the effects of PEDF on cancers in general and osteosarcoma in particular. J Biomed Biotechnol 2012, 2012:740295.
76. Wu J., Wu X., Zhong D., et al. Short hairpin RNA (shRNA) Ether a go-go 1 (Eag1) inhibition of human osteosarcoma angiogenesis via VEGF/PI3K/AKT signaling. Int J Mol Sci 2012, 13:12573-12583.
77. Kuzmanov A., Wielockx B., Rezaei M., et al. Overexpression of factor inhibiting HIF-1 enhances vessel maturation and tumor growth via platelet-derived growth factor-C. Int J Cancer 2012, 131:E603-E613.
78. Klotzsche-von Ameln A., Prade I., Grosser M., et al. PHD4 stimulates tumor angiogenesis in osteosarcoma cells via TGF-alpha. Mol Cancer Res 2013, 11:1337-1348.
79. Hoffman R.M. Fluorescent angiogenesis models using gelfoam(R) implanted in transgenic mice expressing fluorescent proteins. Methods Mol Biol 2014, 1135:213-222.
80. Shukla A., Alsarraj J., Hunter K. Understanding susceptibility to breast cancer metastasis: the genetic approach. Breast Cancer Manag 2014, 3:165-172.
81. Zhu L.B., Jiang J., Zhu X.P., et al. Knockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-kappaB signaling pathway. Int J Clin Exp Pathol 2014, 7:3984-3991.
82. He M.L., Wu Y., Zhao J.M., et al. PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population. Asian Pac J Cancer Prev 2013, 14:5117-5122.
83. Guo Y.S., Zhao R., Ma J., et al. betaig-h3 promotes human osteosarcoma cells metastasis by interacting with integrin alpha2beta1 and activating PI3K signaling pathway. PLoS One 2014, 9:e90220.
84. Hou C.H., Lin F.L., Tong K.B., et al. Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway. Biochem Pharmacol 2014, 89:453-463.
85. Fukaya Y., Ishiguro N., Senga T., et al. A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8. Oncol Rep 2005, 14:847-852.
86. Aizawa J., Sakayama K., Kamei S., et al. Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8. BMC Cancer 2010, 10:51.
87. Tsubaki M., Satou T., Itoh T., et al. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol Appl Pharmacol 2012, 259:402-410.
88. Soderstrom M., Palokangas T., Vahlberg T., et al. Expression of ezrin, Bcl-2, and Ki-67 in chondrosarcomas. APMIS 2010, 118:769-776.
89. Machado I., Navarro S., Giner F., et al. Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors. Virchows Arch 2010, 457:87-89.
90. Chen Q.Y., Xu W., Jiao D.M., et al. Silence of ezrin modifies migration and actin cytoskeleton rearrangements and enhances chemosensitivity of lung cancer cells in vitro. Mol Cell Biochem 2013, 377:207-218.
91. Zhang J., Zuo J., Lei M., et al. Ezrin promotes invasion and migration of the MG63 osteosarcoma cell. Chin Med J (Engl) 2014, 127:1954-1959.
92. Lo Vasco V.R., Leopizzi M., Puggioni C., et al. Ezrin silencing remodulates the expression of Phosphoinositide-specific Phospholipase C enzymes in human osteosarcoma cell lines. J Cell Commun Signal 2014, 8:219-229.
93. Bulut G., Hong S.H., Chen K., et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2012, 31:269-281.
94. Krishnan K., Bruce B., Hewitt S., et al. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis 2006, 23:227-236.
95. Liao Y.X., Zhou C.H., Zeng H., et al. The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (review). Int J Mol Med 2013, 32:1239-1246.
96. Perissinotto E., Cavalloni G., Leone F., et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res 2005, 11:490-497.
97. D'Adamo D.R. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol 2011, 38(Suppl. 3):S19-S29.
98. He H., Ni J., Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (review). Oncol Lett 2014, 7:1352-1362.
99. Zhou Y., Zang X., Huang Z., et al. TWIST interacts with endothelin-1/endothelin A receptor signaling in osteosarcoma cell survival against cisplatin. Oncol Lett 2013, 5:857-861.
100. Wu J., Liao Q., He H., et al. TWIST interacts with beta-catenin signaling on osteosarcoma cell survival against cisplatin. Mol Carcinog 2014, 53:440-446.
101. Zhang B., Shi Z.L., Liu B., et al. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB. Anticancer Drugs 2010, 21:288-296.
102. Liang C., Li H., Shen C., et al. Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-kappaB pathway. Anticancer Agents Med Chem 2012, 12:554-563.
103. Marion A., Dieudonne F.X., Patino-Garcia A., et al. Calpain-6 is an endothelin-1 signaling dependent protective factor in chemoresistant osteosarcoma. Int J Cancer 2012, 130:2514-2525.
104. van Lohuizen M., Verbeek S., Scheijen B., et al. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65:737-752.
105. Wu Z., Min L., Chen D., et al. Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma. PLoS One 2011, 6:e14648.
106. O'Farrill J.S., Gordon N. Autophagy in osteosarcoma. Adv Exp Med Biol 2014, 804:147-160.
107. Joshi P., Middleton J., Jeon Y.J., et al. MicroRNAs in lung cancer. World J Methodol 2014, 4:59-72.
108. Chang Z., Huo L., Li K., et al. Blocked autophagy by miR-101 enhances osteosarcoma cell chemosensitivity in vitro. Sci World J 2014, 2014:794756.
109. Ferreira A.C., Robaina M.C., Rezende L.M., et al. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101. Ann Hematol 2014, 93:983-993.
110. Lee J.W., Kim K.S., An H.K., et al. Dendropanoxide induces autophagy through ERK1/2 activation in MG-63 human osteosarcoma cells and autophagy inhibition enhances dendropanoxide-induced apoptosis. PLoS One 2013, 8:e83611.
111. Ren W., Liu Y., Wan S., et al. BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways. PLoS One 2014, 9:e96816.
112. Liu B., Wu Y., Peng D. Astrocyte elevated gene-1 regulates osteosarcoma cell invasion and chemoresistance via endothelin-1/endothelin A receptor signaling. Oncol Lett 2013, 5:505-510.
113. Gobin B., Huin M.B., Lamoureux F., et al. BYL719, a new alpha-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer 2015, 136:784-796.
114. Edlind M.P., Hsieh A.C. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl 2014, 16:378-386.
115. Manara M.C., Nicoletti G., Zambelli D., et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010, 16:530-540.
116. Gobin B., Battaglia S., Lanel R., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett 2014, 344:291-298.
117. Lehmann B.D., Bauer J.A., Schafer J.M., et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 2014, 16:406.
118. English D.P., Bellone S., Cocco E., et al. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol 2013, 209:e461-e469.
119. Spoerke J.M., O'Brien C., Huw L., et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 2012, 18:6771-6783.
120. Carol H., Morton C.L., Gorlick R., et al. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 2010, 55:1329-1337.
121. Hernandez-Aya L.F., Gonzalez-Angulo A.M. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 2011, 16:404-414.
122. Ghobrial I.M., Roccaro A., Hong F., et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010, 16:1033-1041.
123. Paplomata E., O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Adv Med Oncol 2014, 6:154-166.
124. Xie Z.G., Xie Y., Dong Q.R. Inhibition of the mammalian target of rapamycin leads to autophagy activation and cell death of MG63 osteosarcoma cells. Oncol Lett 2013, 6:1465-1469.
125. Mu X., Isaac C., Schott T., et al. Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells. Sarcoma 2013, 2013:480713.
126. Pignochino Y., Dell'Aglio C., Basirico M., et al. The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res 2013, 19:2117-2131.
127. Fleuren E.D., Versleijen-Jonkers Y.M., Roeffen M.H., et al. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. Int J Cancer 2014, 135:2770-2782.
128. Bagatell R., Norris R., Ingle A.M., et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a children's oncology group study. Pediatr Blood Cancer 2013, 61:833-839.
129. Chawla S.P., Staddon A.P., Baker L.H., et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012, 30:78-84.
130. Wang X., Lai P., Zhang Z., et al. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis. Oncol Rep 2014, 32:382-388.
131. Nielsen-Preiss S.M., Silva S.R., Gillette J.M. Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells. J Cell Biochem 2003, 90:964-975.
132. Song D., Ni J., Xie H., et al. DNA demethylation in the PTEN gene promoter induced by 5-azacytidine activates PTEN expression in the MG-63 human osteosarcoma cell line. Exp Ther Med 2014, 7:1071-1076.
133. Loftus J.P., Cavatorta D., Bushey J.J., et al. The 5-lipoxygenase inhibitor tepoxalin induces oxidative damage and altered PTEN status prior to apoptosis in canine osteosarcoma cell lines. Vet Comp Oncol 2014, [Epub ahead of print].
134. Miwa S., Sugimoto N., Yamamoto N., et al. Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-kappaB and MAPK pathways. Anticancer Res 2012, 32:3643-3649.
135. Millimouno F.M., Dong J., Yang L., et al. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer Prev Res (Phila) 2014, 7:1081-1107.
136. Zhang Y., Sun S., Chen J., et al. Oxymatrine induces mitochondria dependent apoptosis in human osteosarcoma MNNG/HOS cells through inhibition of PI3K/Akt pathway. Tumour Biol 2014, 35:1619-1625.
137. Yang J.S., Lin C.W., Hsieh Y.S., et al. Selaginella tamariscina (Beauv.) possesses antimetastatic effects on human osteosarcoma cells by decreasing MMP-2 and MMP-9 secretions via p38 and Akt signaling pathways. Food Chem Toxicol 2013, 59:801-807.
138. Geng Y.D., Yang L., Zhang C., et al. Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells. Food Chem Toxicol 2014, 73C:7-16.
139. Xie X., Yin J., Jia Q., et al. Quercetin induces apoptosis in the methotrexate-resistant osteosarcoma cell line U2-OS/MTX300 via mitochondrial dysfunction and dephosphorylation of Akt. Oncol Rep 2011, 26:687-693.
140. Liu Y., He J., Chen X., et al. The proapoptotic effect of formononetin in human osteosarcoma cells: involvement of inactivation of ERK and Akt pathways. Cell Physiol Biochem 2014, 34:637-645.
141. Peng S.F., Lee C.Y., Hour M.J., et al. Curcumin-loaded nanoparticles enhance apoptotic cell death of U2OS human osteosarcoma cells through the Akt-bad signaling pathway. Int J Oncol 2014, 44:238-246.